NASDAQ · AXSM
Healthcare · Biotechnology
$207.77
Down-$0.26 (-0.12%)
Updated Aug 22, 2026, 2:43 AM
SID Score
5.5/10
Composite research score
Smart Money
54/100
Neutral
Price performance
1M range · 21 trading sessions · Daily adjusted prices
AXSM closed at $207.77 after 21 trading sessions, down 13.79% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Aug 21, 2026 | $207.22 | $210.87 | $206.498 | $207.77 | 734.95K |
| Aug 20, 2026 | $216.50 | $217.85 | $206.255 | $208.03 | 620.93K |
| Aug 19, 2026 | $218.93 | $222.46 | $216.725 | $218.20 | 572.11K |
| Aug 18, 2026 | $215.93 | $220.005 | $214.39 | $215.69 | 506.35K |
| Aug 17, 2026 | $212.01 | $216.96 | $211.44 | $216.27 | 511.87K |
| Aug 14, 2026 | $211.00 | $216.30 | $208.95 | $213.67 | 476.33K |
| Aug 13, 2026 | $215.76 | $221.55 | $212.63 | $213.68 | 705.32K |
| Aug 12, 2026 | $216.80 | $218.745 | $213.15 | $214.66 | 1.24M |
| Aug 11, 2026 | $222.33 | $223.045 | $215.35 | $215.77 | 834.38K |
| Aug 10, 2026 | $215.88 | $223.40 | $210.00 | $220.89 | 1.4M |
| Aug 7, 2026 | $210.13 | $214.39 | $208.6051 | $212.74 | 1.02M |
| Aug 6, 2026 | $212.73 | $216.56 | $209.975 | $210.13 | 397.25K |
| Aug 5, 2026 | $214.49 | $218.12 | $209.2601 | $212.85 | 665.36K |
| Aug 4, 2026 | $212.81 | $214.89 | $210.13 | $212.17 | 473.52K |
| Aug 3, 2026 | $215.50 | $216.245 | $206.94 | $211.04 | 962.87K |
| Jul 31, 2026 | $234.46 | $235.10 | $217.64 | $217.99 | 782.17K |
| Jul 30, 2026 | $229.25 | $235.21 | $223.71 | $234.64 | 714.36K |
| Jul 29, 2026 | $233.96 | $235.91 | $227.00 | $227.42 | 523.07K |
| Jul 28, 2026 | $241.95 | $242.10 | $232.34 | $234.20 | 404.14K |
| Jul 27, 2026 | $240.43 | $245.495 | $237.08 | $238.37 | 773.05K |
| Jul 24, 2026 | $240.92 | $242.96 | $237.775 | $241.00 | 461.99K |
The latest Smart Investors Daily articles mentioning AXSM.
AXSM research
Company profile and research snapshot.
Axsome Therapeutics Inc is a clinical-stage biopharmaceutical company. It is engaged in developing novel therapies for the management of the central nervous system, or CNS, disorders for which there are limited treatment options. Its pipeline products includes AXS-05, AXS-07, AXS-12, and AXS-14. It manages its business as one operating segment and reporting unit, which is the business of developing and delivering novel therapies for the management of CNS disorders.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Aug 12, 2026 | Mizuho | Outperform | — |
| Aug 11, 2026 | RBC Capital | Outperform | — |
| Aug 11, 2026 | Morgan Stanley | Equal-Weight | — |
| Aug 11, 2026 | Guggenheim | Buy | — |
| Aug 11, 2026 | Wells Fargo | Overweight | — |
No generated briefing is available yet.
Benzinga · Aug 13, 2026
Axsome Therapeutics (NASDAQ:AXSM) has outperformed the market over the past 10 years by 26.64% on an annualized basis producing an average annual return of 40.19%. Currently, Axsome Therapeutics has a market
Benzinga · Aug 12, 2026
Mizuho analyst Graig Suvannavejh maintains Axsome Therapeutics (NASDAQ:AXSM) with a Outperform and raises the price target from $306 to $316.
SeekingAlpha · Aug 11, 2026
Axsome Therapeutics, Inc. Q2 shows 46% revenue growth as Auvelity expands, but SG&A surges and losses persistâclick to read why AXSM stock is a Sell.
Benzinga · Aug 11, 2026
Morgan Stanley analyst Sean Laaman maintains Axsome Therapeutics (NASDAQ:AXSM) with a Equal-Weight and raises the price target from $242 to $251.
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning AXSM.
